The Gazelle Chair delivers Extracorporeal Magnetic Innervation, an FDA-cleared therapy backed by more than 25 years of published research.
CLEARWATER, FL, UNITED STATES, July 15, 2026 /EINPresswire.com/ — Clinical assessments reveal that by the time women reach their late 60s, almost all — up to 97.7 percent — exhibit some form of pelvic organ prolapse, and roughly 62 percent of adult females in the United States, approximately 78 million, experience urinary incontinence. Despite these numbers, many are informed that their options are limited to pads, pharmaceuticals, or surgical intervention. Bedrock Bioscience aims to shift this paradigm. The organization has announced the broader rollout of the Gazelle Chair, a non-surgical solution for urinary incontinence and pelvic floor disorders, now accessible via an expanding group of practitioners across the country. This device utilizes Extracorporeal Magnetic Innervation (ExMI), an FDA-cleared method supported by over 25 years of peer-reviewed literature and employed in the treatment of more than 15,000 individuals throughout the technology’s history.
“For years, I believed that leaking while laughing or running was just an unsolvable part of motherhood — I reached the point where I needed four pads just to get through a 30-minute jog. I was too embarrassed to talk about it, and the surgical options I was given felt like a risk I wasn’t willing to take. After just seven sessions in the Gazelle Chair, the change has been life-changing. I’ve been pad-free for months and have regained the freedom to run and live my life without fear.”
— Kim, Gazelle Chair patient
Individual results may vary.
Bladder leakage impacts nearly 62 percent of adult women across the United States — around 78 million individuals — based on a 2022 peer-reviewed assessment of CDC survey data featured in Urogynecology (formerly Female Pelvic Medicine & Reconstructive Surgery; Patel et al., 2022). Furthermore, the root issue becomes nearly universal with advancing age: upon clinical examination, up to 97.7 percent of women display some level of pelvic organ prolapse — a deterioration of the identical pelvic floor musculature — with both occurrence and intensity rising over time (Lousquy et al., 2009). In spite of the prevalence of these ailments, numerous women silently endure them for years, frequently concluding that their sole alternatives are invasive operations, continuous drug therapy, or perpetual acceptance. The Gazelle Chair is engineered to present women and their healthcare providers with an alternative: a scientifically studied, clinic-based treatment that demands no recovery period and no interruption to everyday routines.
“Too many women are told that bladder leakage is simply something they have to accept after childbirth or menopause. It isn’t. ExMI has more than two decades of clinical evidence behind it, and through the Gazelle Chair we can now offer women a non-invasive, in-office option that involves no surgery, no medication, and no downtime. For providers, it’s a chance to finally address something their patients have been struggling with quietly for years.”
— Clinical Advisor, Bedrock Bioscience
In a Gazelle Chair session, the patient remains fully clothed as a bio-electric magnetic field reaches up to four inches into the body, activating the pelvic floor’s nerves and muscles. These impulses trigger controlled contractions and relaxations of the muscles, reestablishing the communication pathway between the brain and the pelvic floor throughout the treatment series. Since ExMI does not require skin contact or anesthesia, individuals can return to their usual activities straight after a 20-minute appointment.
The scientific foundation for the ExMI technology integrated into the Gazelle Chair covers more than a quarter-century. A 2020 randomized controlled trial published in BioMed Research International contrasted ExMI with conventional pelvic floor muscle exercises, revealing notable enhancements in continence and quality-of-life metrics among those who underwent ExMI (Weber-Rajek et al., 2020). That investigation is one of 46 scholarly articles on ExMI cataloged at gazellechair.com/clinical-studies, covering urology, urogynecology, and pelvic rehabilitation fields. ExMI possesses two 510(k) clearances from the U.S. Food and Drug Administration, is categorized as a Class II powered muscle stimulator, and each Gazelle Chair is constructed in the United States adhering to ISO-13485 quality benchmarks. As with any therapeutic approach, personal outcomes may differ.
As with any magnetic stimulation therapy, ExMI is not appropriate for every patient. Pregnancy, a copper intrauterine device, ferromagnetic implants, a cardiac pacemaker, and severe cardiac arrhythmia are contraindications for ExMI treatment. Patients should discuss their full medical history with a provider before beginning treatment.
“I was one of the first ten providers to bring the Gazelle Chair into my practice, and the response has been remarkable. Women have been searching for a real solution for years, and what keeps me excited is the results they get. It takes very little chair time, and the improvement in their quality of life speaks for itself.”
— Dr. J.L., one of the first Gazelle Chair providers
Bedrock Bioscience possesses the exclusive rights to deliver ExMI technology, under the Gazelle Chair brand, to physicians (MDs), chiropractors (DCs), nurse practitioners (NPs), medspas, and wellness and longevity facilities aiming to provide their patients with a scientifically validated, non-surgical incontinence option. Women can visit gazellechair.com to discover more about the therapy, examine the supporting evidence, and find a participating practitioner in their vicinity.
For more information about the Gazelle Chair, including clinical studies and provider information, visit gazellechair.com.
Ricardo Ruiz
Bedrock Bioscience
+1 760-300-8163
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
